Polylactide Nanocapsules Attenuate Adverse Cardiac Cellular Effects of Lyso-7, a Pan-PPAR Agonist/Anti-Inflammatory New Thiazolidinedione
Lyso-7 is a novel synthetic thiazolidinedione, which is a receptor (pan) agonist of PPAR α,β/δ,γ with anti-inflammatory activity. We investigated the cardiotoxicity of free Lyso-7 in vitro (4.5-450 nM), and Lyso-7 loaded in polylactic acid nanocapsules (NC) in vivo (Lyso-7-NC, 1.6 mg/kg). In previou...
Saved in:
Main Authors: | , , , , , , |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_b584e5f5538e4f4f9a16e6e13cc3c58d | ||
042 | |a dc | ||
100 | 1 | 0 | |a Giani M. Garcia |e author |
700 | 1 | 0 | |a Jérôme Roy |e author |
700 | 1 | 0 | |a Ivan R. Pitta |e author |
700 | 1 | 0 | |a Dulcinéia S. P. Abdalla |e author |
700 | 1 | 0 | |a Andrea Grabe-Guimarães |e author |
700 | 1 | 0 | |a Vanessa C. F. Mosqueira |e author |
700 | 1 | 0 | |a Sylvain Richard |e author |
245 | 0 | 0 | |a Polylactide Nanocapsules Attenuate Adverse Cardiac Cellular Effects of Lyso-7, a Pan-PPAR Agonist/Anti-Inflammatory New Thiazolidinedione |
260 | |b MDPI AG, |c 2021-09-01T00:00:00Z. | ||
500 | |a 10.3390/pharmaceutics13091521 | ||
500 | |a 1999-4923 | ||
520 | |a Lyso-7 is a novel synthetic thiazolidinedione, which is a receptor (pan) agonist of PPAR α,β/δ,γ with anti-inflammatory activity. We investigated the cardiotoxicity of free Lyso-7 in vitro (4.5-450 nM), and Lyso-7 loaded in polylactic acid nanocapsules (NC) in vivo (Lyso-7-NC, 1.6 mg/kg). In previous work, we characterized Lyso-7-NC. We administered intravenously Lyso-7, Lyso-7-NC, control, and blank-NC once a day for seven days in mice. We assessed cell contraction and intracellular Ca<sup>2+</sup> transients on single mice cardiomyocytes enzymatically isolated. Lyso-7 reduced cell contraction and accelerated relaxation while lowering diastolic Ca<sup>2+</sup> and reducing Ca<sup>2+</sup> transient amplitude. Lyso-7 also promoted abnormal ectopic diastolic Ca<sup>2+</sup> events, which isoproterenol dramatically enhanced. Incorporation of Lyso-7 in NC attenuated drug effects on cell contraction and prevented its impact on relaxation, diastolic Ca<sup>2+</sup>, Ca<sup>2+</sup> transient amplitude, Ca<sup>2+</sup> transient decay kinetics, and promotion of diastolic Ca<sup>2+</sup> events. Acute effects of Lyso-7 on cardiomyocytes in vitro at high concentrations (450 nM) were globally similar to those observed after repeated administration in vivo. In conclusion, we show evidence for off-target effects of Lyso-7, seen during acute exposure of cardiomyocytes to high concentrations and after repeated treatment in mice. Nano-encapsulation of Lyso-7 in polymeric NC attenuated the unwanted effects, particularly ectopic Ca<sup>2+</sup> events known to support life-threatening arrhythmias favored by stress or exercise. | ||
546 | |a EN | ||
690 | |a peroxisome proliferator-activated receptor-γ | ||
690 | |a cardiotoxicity | ||
690 | |a metabolic syndrome | ||
690 | |a atherosclerosis | ||
690 | |a contraction | ||
690 | |a calcium transient | ||
690 | |a Pharmacy and materia medica | ||
690 | |a RS1-441 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Pharmaceutics, Vol 13, Iss 9, p 1521 (2021) | |
787 | 0 | |n https://www.mdpi.com/1999-4923/13/9/1521 | |
787 | 0 | |n https://doaj.org/toc/1999-4923 | |
856 | 4 | 1 | |u https://doaj.org/article/b584e5f5538e4f4f9a16e6e13cc3c58d |z Connect to this object online. |